抑制BET会改变免疫微环境,并缓解慢性淋巴细胞白血病中T细胞功能障碍
Audrey L Smith1, Sydney A Skupa1, Alexandria P Eiken1
1Eppley Institute for Research in Cancer and Allied Diseases.
JCI insight
|May 22, 2024
概括
使用 OPN-51107 阻断原蛋白和外端蛋白 (BET) 会使慢性淋巴细胞白血病 (CLL) 中的耗尽的 T 细胞恢复生命. 这种方法减少了免疫抑制,并增强了TME的抗瘤免疫力.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 慢性淋巴细胞白血病 (CLL) 的特点是免疫抑制性瘤微环境 (TME) 和T细胞枯竭,阻碍有效的抗白血病免疫反应.
- 原蛋白和外端蛋白 (BET) 是参与CLL病原和TME调节的通路的关键调节者,包括T细胞功能.
研究的目的:
- 研究BET蛋白抑制对CLL TME内的免疫抑制机制和T细胞缺陷的影响.
- 评估泛BET抑制剂OPN-51107在恢复CLL中T细胞功能的治疗潜力.
主要方法:
- 使用了Eμ-TCL1小鼠模型的CLL和初级人类CLL培养物.
- 服用泛BET抑制剂OPN-51107以评估其对T细胞耗尽标记物,增殖,效应器功能和基因表达的影响.
- 分析了TME组成和T细胞表型,包括抑制性受体表达和转录因子概况.
主要成果:
- 在CLL TME中,BET抑制 (BET-i) 与OPN-51107减少了耗尽特征,改善了T细胞增殖和效应器功能.
- BET-i导致T细胞上抑制性受体 (例如PD-1,LAG3) 的表达减少,并产生促炎作用.
- BET-i通过改变转录因子表达和染色质可访问性来促进原始T细胞表型,增加TCF-1水平.
结论:
- BET抑制有效地缓解免疫抑制网络,并修复CLL中的T细胞缺陷.
- OPN-51107在CLL T细胞上表现出强大的免疫调节作用,超过了常见的向疗法.
- BET 抑制剂通过恢复抗瘤T细胞活性来管理CLL是一个有希望的治疗策略.
相关概念视频
Cell-mediated Immune Responses
68.1K
Overview
68.1K
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Cytotoxic T Cells-mediated Immune Response
892
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
892
Disorders of Leukocytes
938
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
938


